Welcome to our dedicated page for Catalyst Pharmaceutical news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceutical stock.
Catalyst Pharmaceuticals Inc. (CPRX) is a pioneering biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare and debilitating diseases. The company's primary focus lies in addressing chronic neuromuscular and neurological conditions that severely impact patients' lives. Among its core areas are Lambert-Eaton myasthenic syndrome (LEMS), congenital myasthenic syndromes (CMS), infantile spasms, and Tourette's disorder.
Firdapse®, Catalyst's lead candidate, is a proprietary form of amifampridine phosphate designed for the treatment of patients with LEMS. This drug has successfully completed a global, multi-center, double-blinded randomized pivotal Phase 3 trial, yielding positive top-line data. Following these promising results, Catalyst submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA), seeking approval for the treatment of both LEMS and CMS. Notably, Firdapse® has received breakthrough therapy designation and orphan drug designation from the FDA for these conditions. Additionally, Firdapse® stands as the first and only European-approved drug for symptomatic treatment in adults with LEMS.
Catalyst Pharmaceuticals is also advancing CPP-115, a promising candidate for the treatment of infantile spasms, epilepsy, and other neurological conditions. This initiative underscores the company's commitment to addressing unmet medical needs within the realm of rare diseases.
The company boasts a solid financial foundation, enabling sustained investment in research and development, as well as strategic partnerships to enhance its product pipeline. Catalyst's innovative approach and dedication to improving patients' lives make it a significant player in the biopharmaceutical industry.
Latest News:
- Santhera's study reports the results of the 48-week treatment with Vamorolone in patients with Duchenne Muscular Dystrophy (DMD), supporting the long-term efficacy and safety profile of Vamorolone. (Reference: Neurology 2024;102:e208112)
- Financial highlights and recent business updates, including the 2024 outlook and details about an upcoming conference call and webcast on February 29, 2024.
Catalyst Pharmaceuticals (CPRX) announced three new patents related to its flagship product, FIRDAPSE (amifampridine), set to issue in March 2022. These patents strengthen intellectual property protection for FIRDAPSE, the only approved treatment for Lambert-Eaton myasthenic syndrome (LEMS) in adults in the U.S. The new patents cover treatment for all patient metabolizer types and extend patent exclusivity until 2034. The company aims to submit these patents for inclusion in the FDA Orange Book following issuance.
Catalyst Pharmaceuticals (CPRX) announces participation in Rare Disease Day by ringing the Nasdaq opening bell on February 28, 2022. This event highlights the collaboration between the biopharma industry and patient advocacy groups to raise awareness and develop treatments for rare diseases. Approximately 30 million Americans are affected by rare disorders, yet only 5% of these diseases have approved treatments. Catalyst aims to support patients with Lambert-Eaton myasthenic syndrome (LEMS) through its FDA-approved drug FIRDAPSE.
Catalyst Pharmaceuticals announced the launch of a podcast named LEMS Aware aimed at raising awareness within the Lambert-Eaton Myasthenic Syndrome (LEMS) community. The podcast will feature discussions with patients, physicians, and advocates, focusing on topics unique to LEMS. The inaugural episode is set to release on February 28, 2022, coinciding with Rare Disease Day. This initiative underscores Catalyst's commitment to enhancing education and resources for patients, particularly as only 5% of over 7,000 rare diseases have an FDA-approved treatment.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced estimated total revenues for 2021 of approximately $141 million, up 18% year-over-year, with Q4 revenues of around $38 million, a 24% increase from 2020. Looking ahead, the company projects 2022 revenues between $195 million and $205 million, a growth of 38%-45%. Catalyst has regained orphan drug exclusivity in the U.S. for Amifampridine (FIRDAPSE) and enters 2022 with a strong cash position of $191 million and no funded debt, poised for potential acquisitions.
Catalyst Pharmaceuticals has achieved a significant legal victory as the District Court granted summary judgment in its lawsuit against the FDA. This ruling confirms that the FDA's approval of Ruzurgi® for treating pediatric patients with LEMS infringes on Catalyst's exclusivity rights for FIRDAPSE®. Consequently, the FDA's prior marketing approval for Ruzurgi® is invalid. Catalyst is prepared to assist patients transitioning from Ruzurgi® to FIRDAPSE®, ensuring uninterrupted treatment. The company remains focused on developing medicines for rare diseases.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that the U.S. Court of Appeals for the 11th Circuit has favored the company in its lawsuit against the FDA, which will vacate FDA's approval of Ruzurgi, a competing amifampridine product. CEO Patrick J. McEnany stated the company is committed to ensuring patients' access to amifampridine for Lambert-Eaton myasthenic syndrome (LEMS). FIRDAPSE, Catalyst's approved treatment, remains available in the U.S. and Canada. The announcement notes potential risks related to further legal appeals and outcomes affecting Catalyst's future operations.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced that the 11th Circuit Court of Appeals denied Jacobus Pharmaceutical's petition for rehearing regarding the FDA's approval of Ruzurgi® for pediatric LEMS patients. This ruling supports Catalyst's position and anticipates a forthcoming mandate for summary judgment in their favor. CEO Patrick J. McEnany emphasized the company's commitment to patient care, ensuring uninterrupted access to amifampridine, whether through commercial or compassionate use programs. Catalyst aims to provide the necessary support to patients transitioning to FIRDAPSE.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) announced that Patrick J. McEnany, Chairman and CEO, along with Dr. Steven Miller, CSO/COO, will participate in two investor conferences:
- Solebury Trout 1x1 Management Access Event: January 10-20, 2022, featuring one-on-one virtual meetings.
- H.C. Wainwright Global BIOCONNECT Virtual Conference: January 10-13, 2022, with a pre-recorded corporate presentation available on-demand.
Catalyst focuses on developing novel medicines for rare diseases, including FIRDAPSE® for Lambert-Eaton myasthenic syndrome.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced a significant milestone as its partner, DyDo Pharma, initiates a Phase 3 clinical study in Japan for FIRDAPSE® (amifampridine) targeting Lambert-Eaton myasthenic syndrome (LEMS). Currently, no approved treatments exist for this rare disorder in Japan. Catalyst's collaboration with DyDo, formalized through a sub-license agreement in June 2021, strengthens the potential for FIRDAPSE® to become a novel therapy in the region. The company will supply clinical and commercial support, earning milestones and revenue contingent on regulatory approval.
Catalyst Pharmaceuticals (Nasdaq: CPRX) announced participation in the Piper Sandler 33rd Annual Virtual Healthcare Conference from November 29 to December 2, 2021. CEO Patrick J. McEnany and COO Steven Miller will engage in a pre-recorded fireside chat. A webcast of this discussion will be available on the company's website starting November 22, 2021, at 10:00 a.m. ET. Catalyst focuses on developing high-quality medicines for rare diseases, with its product FIRDAPSE approved by the FDA in 2018.
FAQ
What is the current stock price of Catalyst Pharmaceutical (CPRX)?
What is the market cap of Catalyst Pharmaceutical (CPRX)?
What does Catalyst Pharmaceuticals Inc. focus on?
What is Firdapse®?
What recent progress has Firdapse® made?
What other products is Catalyst developing?
Has Firdapse® been approved for use in Europe?
How is Catalyst Pharmaceuticals financially positioned?
What is Catalyst's approach to drug development?
What recent news is there about Catalyst Pharmaceuticals?
When is Catalyst's next conference call and webcast?